Metabolic and Prolonged Satiety Effects of a Breakfast Kit
1 other identifier
interventional
15
1 country
1
Brief Summary
The mobilizing programme MobFood - mobilizing scientific knoweledge and technology to answer the current nutrition market challenges - is formed by a consortium of 47 collaborative entities, between the industry and ENESIIs (Entidades Não Empresariais do Sistema de Investigação e Inovação) and is financed by Structural European Funds of Investment. The project is currently investigating and undertaking collaborative scientific and technological strategies based on R\&D and innovation, in order to boost and promote a more competitive national food industry, capable of overcoming the current challenges, including those of the Millennial Generation. This group is particularly conscious of the impact of food behaviour and food choices on health but extremely vulnerable to dietary imbalance. Strategies to improve Millenials' nutrition while providing conscious food products are needed. This study is a randomised, cross-over controlled trial designed to test the metabolic effect, particularly in terms of appetite control and glycaemic response of a breakfast kit (nutritionally balanced and innovative), recently developed as part of the collaborative project MobFood\_PPS4.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2020
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 1, 2020
CompletedStudy Start
First participant enrolled
June 1, 2020
CompletedFirst Posted
Study publicly available on registry
June 4, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2020
CompletedJune 9, 2020
November 1, 2019
4 months
June 1, 2020
June 4, 2020
Conditions
Outcome Measures
Primary Outcomes (6)
Differences in the incremental area under the curve (iAUC, mg/dl*min) for glucose response between the 2 arms
The iAUC for glucose will be calculated based on the concentration curve following consumption of the test and control products, over 2h
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Differences in the iAUC (pmol/l*min) for glucagon-like peptide-1 (GLP-1) between the 2 arms
The iAUC for GLP-1 will be calculated based on the concentration curve following consumption of the test and control products, over 3h
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Differences in the iAUC (pmol/l*min) for peptide YY (PYY) between the 2 arms
The iAUC for PYY will be calculated based on the concentration curve following consumption of the test and control products, over 3h
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Differences in the iAUC (pmol/l*min) for cholecystokinin (CKK) between the 2 arms
The iAUC for CKK will be calculated based on the concentration curve following consumption of the test and control products, over 3h
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Differences in the iAUC (pmol/l*min) for ghrelin between the 2 arms
The iAUC for ghrelin will be calculated based on the concentration curve following consumption of test and control products, over 3h
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Differences in the iAUC (pmol/l*min) for glucagon between the 2 arms
The iAUC for glucagon will be calculated based on the concentration curve following consumption of the test and control products, over 3h
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Secondary Outcomes (3)
Differences in the iAUC (mg/dl*min) for triacylglycerides (TG) between 2 arms
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Differences in the iAUC for (mmol/l*min) non-esterified fatty acids (NEFA) between 2 arms
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Differences in subjective feelings of hunger/satiety between the 2 arms
at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)
Study Arms (2)
MobFood breakfast kit
EXPERIMENTALControl isocaloric breakfast
EXPERIMENTALInterventions
Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood\_PPS4.
Eligibility Criteria
You may qualify if:
- Male or female;
- Born between 1981 and 1996;
- Body mass index (BMI) between 18.5 kg/m2 and 24.9 kg/m2;
- Normoglycemic according to American Diabetes Association criteria \[Fasting Plasma Glucose \< 100 mg/dl, 2-h plasma glucose value during a 75 g oral glucose tolerance test (OGTT) \< 140 mg/dl)\];
- Healthy.
You may not qualify if:
- Overweight or obese (BMI ≥ 25,0 kg/m2);
- Recent body weight loss/gain \>10%, within previous 3 months;
- Being on a weight loss/other special diet (e.g. Paleo diet, Atkins diet, flexitarian diet or ketogenic diet), within previous 3 months;
- Clinically significant illness, including:
- type 1 or type 2 diabetes; liver disease e.g. cirrhosis; malignancy; pancreatitis or other malabsorption; gastrointestinal disorders e. g. intestinal bowel disorder, celiac disease; previous weight loss surgery e.g. bariatric surgery; chronic respiratory, neurological, psychiatric, musculoskeletal diseases/conditions; diagnosed eating disorders.
- Individuals who don't regularly consume breakfast;
- Having taken antibiotics within the 12 weeks prior to beginning the study;
- Taking other medication that could potentially affect body weight, glucose metabolism and/or appetite (e.g. GLP-1 analogues);
- Being engaged in competitive sports;
- Having \>14 or \>8 (males and females, respectively) alcoholic units/week; misuse of drugs;
- Having donated blood within one month prior to the beginning of the study;
- Nut or milk allergy, or other food allergy or intolerance that would compromise compliance with the study protocol;
- Pregnant or breastfeeding.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universidade do Portolead
- Center for Health Technology and Services Researchcollaborator
- NOVA Medical Schoolcollaborator
Study Sites (1)
NOVA Medical School, NOVA University of Lisbon
Lisbon, Portugal
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 1, 2020
First Posted
June 4, 2020
Study Start
June 1, 2020
Primary Completion
September 30, 2020
Study Completion
October 31, 2020
Last Updated
June 9, 2020
Record last verified: 2019-11